105390Re-engineering T-cell membranes for efficacy against solid tumoursClosedCollaborative R&DInnovate UKIn 2018, more than 9.5 million people worldwide died from cancer, with more than 18 million new cancer incidences reported. A new approach using human immune cells to attack tumours is showing promise in the clinic. Within this exciting new field, CAR-T therapy has been shown to be effective against blood-based cancers, such as acute lymphoblastic leukaemia. Unfortunately, cancers that involve the formation of solid tumours, which make up 85% of cancer deaths worldwide, are resistant to current cellular immunotherapies, which severely limits the range of treatments available to the public. In an effort to overcome this limitation, CytoSeek has teamed up with the University of Birmingham (UoBi) to develop a new class of smart CAR-T that can attack solid tumours. The collaboration involves applying CytoSeek cell painting technology to "supercharge" the immune cells and allow them to invade and kill cancer cells in solid tumours.